Literature DB >> 22684694

Acute renal failure: a rare side effect of sunitinib therapy.

Hameem I Kawsar1, Saurabh Bansal, Jonathan L Myles.   

Abstract

Sunitinib is an oral multiple tyrosine kinase receptor inhibitor. It is usually well tolerated but can cause fatigue, malaise, and rash. Sunitinib-induced cardiotoxicity has been well described, but nephrotoxicity is very rare. Here, we report a rare case of acute renal failure caused by sunitinib therapy in a 73-year-old Caucasian female who was enrolled in a phase II trial of sunitinib therapy for clear cell ovarian cancer. At presentation, her blood urea nitrogen (BUN) was 91 mg/dl and creatinine was 9.2 mg/dl. Sunitinib therapy was discontinued, and she was treated conservatively with intravenous fluid. Creatinine gradually returned to normal, and fatigue resolved. She was diagnosed with sunitinib-induced acute renal failure. The nephrologists and oncologists should be aware of sunitinib-induced rare nephrotoxicity, and patients should be closely monitored.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684694     DOI: 10.1007/s12032-012-0272-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  8 in total

1.  Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.

Authors:  Tae Joon Lim; Jee Han Lee; Sung-Goo Chang; Choong Hyun Lee; Gyeong Eun Min; Koo Han Yoo; Seung Hyun Jeon
Journal:  Urol Int       Date:  2010-10-26       Impact factor: 2.089

2.  Sunitinib-induced myxedema coma.

Authors:  Shey-Ying Chen; Pei-Chieh Kao; Zhong-Zhe Lin; Wen-Chu Chiang; Cheng-Chung Fang
Journal:  Am J Emerg Med       Date:  2009-03       Impact factor: 2.469

Review 3.  Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature.

Authors:  Kenar D Jhaveri; Carlos D Flombaum; Glenn Kroog; Ilya G Glezerman
Journal:  Nephron Clin Pract       Date:  2010-11-03

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].

Authors:  Ezequiel Rodríguez-Reimúndes; Florencia Perazzo; Antonio R Vilches
Journal:  Medicina (B Aires)       Date:  2011       Impact factor: 0.653

6.  Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.

Authors:  M L Telli; R M Witteles; G A Fisher; S Srinivas
Journal:  Ann Oncol       Date:  2008-04-23       Impact factor: 32.976

Review 7.  Renal effects of anti-angiogenesis therapy: update for the internist.

Authors:  Faina Gurevich; Mark A Perazella
Journal:  Am J Med       Date:  2009-04       Impact factor: 4.965

8.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

Authors:  Tammy F Chu; Maria A Rupnick; Risto Kerkela; Susan M Dallabrida; David Zurakowski; Lisa Nguyen; Kathleen Woulfe; Elke Pravda; Flavia Cassiola; Jayesh Desai; Suzanne George; Jeffrey A Morgan; David M Harris; Nesreen S Ismail; Jey-Hsin Chen; Frederick J Schoen; Annick D Van den Abbeele; George D Demetri; Thomas Force; Ming Hui Chen
Journal:  Lancet       Date:  2007-12-15       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.